Prescription Drug Pricing, Purchasing And Coverage: A Look At 2023 And Beyond (Video)

Insilico Medicine has reported that Rentosertib, an AI-discovered clinical candidate for idiopathic pulmonary fibrosis, demonstrates effectiveness in reversing the predicted biological age of IPF patients according to six independent proteomic aging clocks. The molecule's dual-purpose approach—targeting both a diagnosable disease and biological aging simultaneously—may open new pathways for anti-aging therapies...

The False Claims Act’s qui tam provisions are among the federal government’s most important tools for identifying and pursuing alleged fraud involving Medicare, Medicaid, federal health care programs and other government funds. The statute permits a private individual, known as a relator, to bring a False Claims Act action “for the person and for the United States Government” in the name of the government.

The FDA, in collaboration with federal partners, held a landmark public hearing on September 14, 2026, to gather input on the future therapeutic use of psychedelic drugs, drawing over 18,000 registered attendees. This hearing represents one of the earliest implementations of Executive Order 14401, which directs federal agencies to expedite research, review, and approval of psychedelic drugs for serious mental health conditions.

InvaGen Pharmaceuticals Inc., a Cipla Limited subsidiary, has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. for the licensing and supply of QL2107, a biosimilar to Merck's KEYTRUDA® (pembrolizumab), in the United States. This collaboration represents the latest in a series of partnering transactions directed to pembrolizumab biosimilar candidates, with Qilu handling development and regulatory registration while Cipla USA manages commercialization.

The No Surprises Act's Independent Dispute Resolution process is undergoing a major technology transformation with a new centralized portal for open negotiations. This development introduces standardized procedures for billing disputes between healthcare providers and payers, but also raises critical questions about compliance, system capacity, and whether the portal adequately addresses persistent challenges in payment collection and claim eligibility determination.

Diagnosis coding practices in the Medicare Advantage (“MA”) risk adjustment space continue to be a top enforcement priority for the Department of Justice (“DOJ”).

Hospital and health system counsel face unprecedented challenges as AI transforms patient data into a critical asset, requiring navigation of complex de-identification strategies, state AI and privacy law compliance, and model ownership issues. This session provides in-house legal teams with a practical framework for managing AI-driven healthcare data transactions and governance structures they were never formally trained to handle.

Pharmacies frequently engage marketers, develop relationships with prescribers and offer services intended to attract and retain patients. While these efforts can support legitimate business growth, arrangements involving referral payments, copay waivers or free services may create significant regulatory and contractual exposure.

Organizations rushing to adopt AI often focus on eliminating all risks, inadvertently stalling beneficial implementations. This analysis explores how healthcare institutions can establish clear risk tolerance thresholds and implement multi-layered compliance frameworks that enable responsible AI adoption while maintaining appropriate safeguards and oversight mechanisms.

The US Department of Health and Human Services Office of Inspector General recently issued an unfavorable advisory opinion regarding physician consulting arrangements with compensation tied to product line sales, raising concerns about the medical device industry's approach to royalty payments.

Diagnosis coding practices in the Medicare Advantage (“MA”) risk adjustment space continue to be a top enforcement priority for the Department of Justice (“DOJ”).

As entertainment lawyers, we are often asked a deceptively simple question by creatives, producers, and studios: “Can we use this trademark in our project?”

On August 26, 2026, NLRB General Counsel Crystal S. Carey issued Memorandum GC 26-04, “Further Guidance Regarding General Counsel Priorities.” The memo is her second in as many months and reads like a punch list for reversing the Board’s Biden-era precedent. For employers, the headline is simple: nothing has changed yet, but a lot may be about to.

A recent Seventh Circuit decision is a reminder of BIPA’s financial institution GLBA exceptions. In that case, the court held that a vendor to GLBA-regulated entities was exempt from Illinois’ biometric law.

Artificial Intelligence (“AI”) is increasingly moving beyond clinical decision support and into the administrative functions that directly impact healthcare reimbursement.

A publicly traded fintech company has announced a $590 million acquisition of its longtime national bank partner, marking a strategic shift from the traditional bank-partnership model to direct ownership of a national bank charter. The transaction, expected to close in the first half of 2027 pending regulatory approvals, would make the fintech a bank holding company while consolidating its banking activities and eliminating certain sponsor-bank fees. This deal represents a faster alternative to pursuing a d

New York Attorney General Letitia James has released final rules for the Stop Addictive Feeds Exploitation (SAFE) for Kids Act. The law was signed in 2024, but the effective date was triggered by the release of these rules.

On August 20, the District of Columbia’s Medical Debt Mitigation Amendment Act of 2026 became effective after being enacted without Mayor Muriel Bowser’s signature.

On September 1, the Texas Department of Banking issued a consent order resolving allegations that an escrow service provider conducted money transmission activity in Texas without obtaining a license.

On August 31, California Business and Consumer Services Agency (BCSA) Secretary Rohit Chopra announced that examining businesses’ use of emerging technologies...